Research programme: eye disorder therapies - Envisia Therapeutics

Drug Profile

Research programme: eye disorder therapies - Envisia Therapeutics

Alternative Names: AR 1105; Controlled-release bevacizumab intravitreal implant - Envisia; Dexamethasone ophthalmic - Envisia Therapeutics; Dexamethasone ophthalmic - Liquidia Technologies; Difluprednate ophthalmic - Envisia Therapeutics; Difluprednate ophthalmic - Liquidia Technologies; ENV 1105; ENV 1305; ENV 705; ENV 905; Extended release anti-VEGF therapy - Envisia; Extended-release bevacizumab - Envisia; Research programme: eye disorder therapies - Liquidia Technologies

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Liquidia Technologies
  • Developer Envisia Therapeutics
  • Class Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Prostaglandins; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Eye disorders; Postoperative inflammation; Postoperative pain; Wet age-related macular degeneration

Most Recent Events

  • 05 Oct 2017 Preclinical development is ongoing in Eye disorders in USA
  • 05 Oct 2017 Aerie Pharmaceuticals acquires intellectual property rights related to ENV 1105 from Envisia Therapeutics
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Eye-disorders in USA (Ophthalmic, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top